Clinical impact of immunoglobulin heavy chain repertoire in mantle cell lymphoma: A study from the Fondazione Italiana Linfomi (FIL) Phase III MCL0208 trial.

Hemasphere · 2026 · PMC12816975 · PMID 41568240

Europe PMC DOI

hedged sentence

0.0840

closest p · 1.7× alpha

0.0840

boldest claim

The sentences

a nonsignificant trendP = 0.084so close (0.05 < p ≤ 0.1)

11%, respectively, P = 0.049) and a nonsignificant trend toward a lower frequency of TP53 disruption compared to the rest of the cohort (3.8% vs. 17%, P = 0.084, Table S3 ).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.